RenovoRx, Inc. (RNXT)

NASDAQ: RNXT · Real-Time Price · USD

1.240

+0.020 (1.64%)

Aug 14, 2025, 11:28 AM - Market open

RenovoRx Employees

RenovoRx had 10 employees as of December 31, 2024. The number of employees increased by 2 or 25.00% compared to the previous year.

Employees

10

Change (1Y)

2

Growth (1Y)

25.00%

Revenue / Employee

$24,000

Profits / Employee

-$1,015,800

Market Cap

45.35M

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2024	10	2	25.00%
Dec 31, 2023	8	-1	-11.11%
Dec 31, 2022	9	3	50.00%
Dec 31, 2021	6	-3	-33.33%
Dec 31, 2020	9	-	-

Related Stocks

Company Name	Employees
UnitedHealth Group	400,000
Johnson & Johnson	138,100
Thermo Fisher Scientific	125,000
Abbott Laboratories	114,000
AstraZeneca	92,900
Novo Nordisk	77,349
Novartis AG	75,883
Merck & Co.	75,000

Employee Rankings

RNXT News

8 days ago - RenovoRx Expands U.S. Commercialization Efforts for the RenovoCath® Device with Growing Customer Demand and Key Leadership Hire - GlobeNewsWire
17 days ago - RenovoRx Launches Multi-Center Post-Marketing Registry Study to Evaluate Cancer Treatment Delivered by RenovoCath® Device to Solid Tumors - Business Wire
4 weeks ago - RenovoRx to Host Second Quarter 2025 Financial Results and Business Highlights Conference Call on August 14th at 4:30 p.m. ET - Business Wire
3 months ago - RenovoRx, Inc. (RNXT) Q1 2025 Earnings Conference Call Transcript - Seeking Alpha
3 months ago - RenovoRx Reports First Quarter 2025 Financial Results and Business Highlights - Business Wire
3 months ago - RenovoRx to Participate in Fireside Chat at A.G.P. Virtual Healthcare Company Showcase on May 21st - Business Wire
3 months ago - U.S. Patent Office Issues New Patent to RenovoRx for Novel Trans-Arterial Micro-Profusion (TAMP™) Therapy Platform - Business Wire
3 months ago - RenovoRx to Host First Quarter 2025 Financial Results Conference Call on May 15th at 4:30 p.m. ET - Business Wire